The landscape of clinical trials is evolving. The changes that are happening are due to the increased number of FDA-regulated trials, as well as a rise in the complexity of clinical protocols. As these protocols are becoming increasingly intricate, the need for highly functioning clinical quality systems is even more important.
Quality systems were originally a construct of Good Manufacturing Practice (GMP). However, regulatory authorities now expect that clinical trials are governed by efficient and practiced quality systems with respect to Good Clinical Practice (GCP).
Most Sponsors utilize services from Contract Research Organizations (CROs) to effectuate some or all of their clinical trial activity. While delegating responsibilities to CROs may be the most efficient model for some Sponsors, the Sponsor is still responsible for ensuring the trials are being executed in a safe, accurate, and reliable manner. The most common deficiencies noted regarding Sponsor and CRO oversight are as follows:
Specifically, regulatory authorities have consistently and regularly cited Sponsors and CROs for deficiencies in the following categories concerning clinical quality systems:
Clinical quality systems play a critical role in the Sponsor’s oversight and the CRO’s operations. The aforementioned deficiencies can be avoided via thoughtful planning that is prompted and required by efficient quality systems. Clinical quality systems mitigate risk in a number of ways, including:
When delegating tasks to a CRO, a common misconception is that the Sponsor has also delegated ultimate responsibility of the integrity and quality of the data. This fallacy has led to many FDA observations/findings. Sponsors should maintain a basic clinical quality system that serves as a foundation for overall strategy and management of their clinical trials. Even with the use of a CRO, the Sponsor should have a vendor management plan that includes selection and oversight of critical service vendors. The Sponsor is responsible for selecting an appropriate CRO with adequate clinical quality systems to manage elements under their purview, and designated in the transfer of obligations.
In the past decade, the FDA has made great efforts to emphasize the importance of quality systems in clinical trials, including the formation of the Clinical Trials Transformation Initiative (CTTI). The group is now comprised of several agencies such as the National Institutes of Health (NIH), the Office of Human Research Protections (OHRP) and other industry representatives. The core commitment and mission of the organization is to develop and implement practices that will increase the quality and efficiency of clinical trials among all stakeholders.
Although the inception of quality systems was to mitigate GMP compliance risk, clinical quality systems within the GCP framework are now the standard expectation for maintaining compliance with regard to designing, implementing, and managing clinical trials in all constructs. While it can be perceived as an insurmountable endeavor, we are here to tell you that it can be done, and done efficiently and painlessly. ProPharma Group can help you develop and implement a successful quality system today. For more information on analyzing your clinical quality system needs, please contact us today.
If you have any questions or thoughts on this blog post or others, please contact us today.
November 17, 2021
One essential consideration in clinical trial development is whether the trial will represent a given population. The most representative trials use recruitment techniques and advanced statistical...
March 27, 2023
ProPharma applauds the myriad of recent, positive developments for clinical trials in the UK, representing the biggest overhaul in UK clinical trials in two decades. Lord O’Shaughnessy Clinical Trial...
March 26, 2018
On Monday, March 19th, the FDA officially began a new Clinical Data Summary Pilot Program. This program is intended to “assess the feasibility of using a different format to provide required...